Biomerica, Inc. (BMRA)

In the past six months, Biomerica's stock has been impacted by several events. Medicare set a national payment rate for its inFoods® IBS test, and the Egyptian Drug Authority authorized Biomerica's complete screening test portfolio. Q2 Fiscal 2026 financial results showed a decrease in revenue but an improved net loss. Biomerica entered into a marketing services agreement with Henry Schein for its inFoods® IBS test in the U.S. Biomerica received an extension from Nasdaq to meet the minimum bid price requirement and implemented a 1-for-8 reverse stock split.

While specific details on overall demand seasonality are limited, Biomerica experienced fewer over-the-counter retail sales during the fourth quarter of fiscal year 2025. The timing of international orders in the first quarter of fiscal year 2026 was impacted by global tariff tensions. The company has also noted a shift in product mix, with increased sales from its inFoods® IBS product offsetting some headwinds.

Biomerica, Inc. is a global biomedical technology company focused on developing, manufacturing, and marketing diagnostic and therapeutic products for gastrointestinal and inflammatory diseases, food intolerances, diabetes, and esoteric tests. Its key products include the inFoods® IBS test, Fortel® Ulcer Test, EZ Detect™ colorectal screening tests, and Aware® breast self-exam products.

Biomerica, Inc. has a global presence with revenue generated from Asia, Europe, North America, the Middle East, and South America. The company uses a global distribution and sales network to reach healthcare providers and laboratories worldwide.

Biomerica's brand reputation has a consensus rating of "Sell" based on analyst sentiment, but a recent decrease in short interest could indicate improving investor sentiment. Clinical studies for its inFoods® IBS test at institutions like Mayo Clinic and Harvard Medical School Teaching Hospital contribute to its scientific credibility. The approval of its screening test portfolio in Egypt and the Medicare payment rate for its IBS test are positive developments.

As of late 2025, institutional investors hold approximately 22.28% of Biomerica's stock, while insiders hold 15.39%. Major institutional owners include Vanguard Group Inc., Geode Capital Management, LLC, and BlackRock, Inc.